CTOR Citius Oncology, Inc.
Listings ·
Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million.
Nasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance.
Citius Oncology signed a warrant inducement worth about $11.5 million and a loan of up to $25.0 million with Avenue. Existing warrants are repriced to $0.90, and the new warrants and conversion rights add to the share count.
Citius Oncology signed a loan of up to $25 million with an Avenue Capital fund and expects about $11.5 million gross from a warrant exercise. Only $10 million of the loan funds at closing, and the new warrants cannot be exercised until stockholders approve the shares.
Nasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026 to cure, while its auditor has flagged going-concern doubt and its parent funds most operations.
Citius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern.
Citius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price.
The company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31.
Citius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes.
Citius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed.
Citius Oncology is a biopharmaceutical company headquartered in Cranford, New Jersey, that develops and commercializes targeted oncology therapies. Its strategy centers on new formulations of previously approved drugs and expanded indications for approved therapies. Its lead product is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The FDA approved LYMPHIR in August 2024 and the product launched in December 2025. The company estimates the market for LYMPHIR to exceed $400 million and describes it as underserved by existing treatments. It plans to commercialize its products independently in the U.S. and to partner for sales outside the U.S., with a small sales force focused mainly on major cancer centers. The license came from Eisai Co., Ltd., and the related asset purchase from Dr. Reddy's Laboratories SA. Citius Pharma owned approximately 77.9% of the company as of December 17, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| LYMPHIR (denileukin diftitox-cdxl) | Engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent cutaneous T-cell lymphoma | approved in the US in August 2024; launched in December 2025 |
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | $6.4 million | $4.9 million |
| Net income (loss) | -$24.8 million | -$21.1 million |
| Cash from operations | -$5.5 million | $126,353 |
| Cash and equivalents | $3.9 million | $112 |
Our latest story on this, dated Apr 28, 2026: "Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 24, 2026: "Citius Pharmaceuticals prices $5 million registered direct offering at $0.985". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 28, 2026: "Citius Oncology gets Nasdaq minimum bid price deficiency notice, has until October 19, 2026". The story links the filing or release it is based on. Read the story.
Citius Oncology, Inc. trades under the ticker CTOR on NASDAQ.
Citius Oncology, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Citius Oncology, Inc. is 1851484. Its filings are on SEC EDGAR.
92,981,204 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Citius Oncology, Inc. under United States.
Our directory classifies Citius Oncology, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Citius Oncology, Inc. is US17331Y1091.
aibio.space lists Citius Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Citius Oncology is a biopharmaceutical company headquartered in Cranford, New Jersey, that develops and commercializes targeted oncology therapies. Its strategy centers on new formulations of previously approved drugs and expanded indications for approved therapies.
LYMPHIR (denileukin diftitox-cdxl): Engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent cutaneous T-cell lymphoma Stage: approved in the US in August 2024; launched in December 2025.
Citius Oncology, Inc. reported a net loss of $24.8 million for the fiscal year ended Sep 30, 2025, and used $5.5 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form S-3. Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio